SCYNEXIS, Inc.

NASDAQ:SCYX

1.27 (USD) • At close September 6, 2024
Bedrijfsnaam SCYNEXIS, Inc.
Symbool SCYX
Munteenheid USD
Prijs 1.27
Beurswaarde 48,077,755
Dividendpercentage 0%
52-weken bereik 1.265 - 3.66
Industrie Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Mr. David Gonzalez Angulo M.D.
Website https://www.scynexis.com

An error occurred while fetching data.

Over SCYNEXIS, Inc.

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal

Vergelijkbare Aandelen

Bolt Biotherapeutics, Inc. logo

Bolt Biotherapeutics, Inc.

BOLT

0.648 USD

Bionomics Limited logo

Bionomics Limited

BNOX

0.595 USD

Qilian International Holding Group Limited logo

Qilian International Holding Group Limited

QLI

5.41 USD

Oncolytics Biotech Inc. logo

Oncolytics Biotech Inc.

ONCY

0.958 USD

Rain Therapeutics Inc. logo

Rain Therapeutics Inc.

RAIN

1.21 USD

Novo Integrated Sciences, Inc. logo

Novo Integrated Sciences, Inc.

NVOS

0.285 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)